Suven Life Sciences is currently trading at Rs. 65.65, up by 4.60 points or 7.53% from its previous closing of Rs. 61.05 on the BSE.
The scrip opened at Rs. 62.75 and has touched a high and low of Rs. 68.60 and Rs. 62.75 respectively. So far 218618 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 94.49 on 13-Jan-2022 and a 52 week low of Rs. 57.10 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 68.60 and Rs. 60.30 respectively. The current market cap of the company is Rs. 1431.65 crore.
The promoters holding in the company stood at 64.98%, while Institutions and Non-Institutions held 0.60% and 34.42% respectively.
Suven Life Sciences has randomized first patient in the Phase-3 global clinical trial of Masupirdine for the treatment of agitation in patients with dementia of the Alzheimer's type. The trial is a multicenter, randomized, double-blind, placebo-controlled study planned across 50 sites in the North America and Europe. The study will enroll around 375 patients who will be randomized in a 1:1:1 ratio to receive masupirdine either 50 mg QD or 100 mg QD or placebo QD for 12 weeks. The primary outcome measure is Cohen-Mansfield Agitation Inventory (CMAI) - Change in the CMAI items score aligning to the International Psychogeriatric Association (IPA) agitation criteria domains from baseline to Week 12. Key secondary outcome measure is modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGI-C) scale as related to the agitation. Topline data from the trial is expected to be available by early 2025.
Suven Life Sciences provides wide range of Drug Discovery and Development Support Services (DDDSS) to global Pharma and Biotech companies. Suven has state-of-art facilities with highly qualified & experienced team of scientists.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
